Fig. 2 | Scientific Reports

Fig. 2

From: Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia

Fig. 2

Clinical outcome stratified according to proportion of MSCs-l at end of treatment for all patients treated with intensive chemotherapy. (A) Overall survival (MSCs-l < 0.265%, n = 48, and MSCs-l ≥ 0.265%, n = 17; HR = 4.941 (95% CI 2.409–10.136). (B) Relapse-free survival (MSCs-l < 0.265%, n = 40, and MSCs ≥ 0.265%, n = 11; HR = 2.630 (95% CI 1.083–6.387). MSCs-l, mesenchymal stem cells-like.

Back to article page